Preclinical studies in multiple tumor cell lines have shown that the anti-angiogenic effects of sunitinib are mediated through VEGFR and PDGFR-β, however the primary target of sunitinib is likely to be VEGFR-2 [39]. This evidence concerns the gene KDR and neoplasm.